$957 Million is the total value of Bellevue Group AG's 134 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 25.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Buy | CELGENE CORP | $42,191,000 | -12.9% | 404,265 | +21.6% | 4.41% | -13.0% |
| ANTM | Buy | ANTHEM INC | $40,788,000 | +25.5% | 181,243 | +5.9% | 4.26% | +25.4% |
| ISRG | Buy | INTUITIVE SURGICAL INC | $35,083,000 | +10.5% | 96,131 | +216.5% | 3.66% | +10.3% |
| UNH | Buy | UNITEDHEALTH GROUP INC | $31,506,000 | +18.1% | 142,910 | +4.9% | 3.29% | +17.9% |
| ABT | Buy | ABBOTT LABS | $30,247,000 | +12.7% | 530,000 | +5.4% | 3.16% | +12.6% |
| INCY | Buy | INCYTE CORP | $21,933,000 | +28.4% | 231,576 | +58.2% | 2.29% | +28.2% |
| WBA | Buy | WALGREENS BOOTS ALLIANCE INC | $21,536,000 | +6.5% | 296,560 | +13.2% | 2.25% | +6.4% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $20,943,000 | +24.2% | 155,582 | +35.0% | 2.19% | +24.1% |
| HOLX | Buy | HOLOGIC INC | $20,686,000 | +55.3% | 483,894 | +33.3% | 2.16% | +55.1% |
| ABC | Buy | AMERISOURCEBERGEN CORP | $19,369,000 | +18.2% | 210,941 | +6.5% | 2.02% | +18.0% |
| DHR | Buy | DANAHER CORP DEL | $18,750,000 | +37.6% | 202,000 | +27.2% | 1.96% | +37.5% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $15,639,000 | +29.6% | 130,770 | +52.1% | 1.63% | +29.5% |
| DXCM | Buy | DEXCOM INC | $15,306,000 | +595.1% | 266,740 | +492.8% | 1.60% | +595.2% |
| VRTX | Buy | VERTEX PHARMACEUTICALS INC | $14,418,000 | +58.6% | 96,210 | +60.9% | 1.51% | +58.4% |
| SYK | Buy | STRYKER CORP | $14,137,000 | +18.1% | 91,300 | +8.3% | 1.48% | +18.0% |
| TEVA | Buy | TEVA PHARMACEUTICAL INDS LTDsponsored adr | $12,733,000 | +24.4% | 671,940 | +15.5% | 1.33% | +24.2% |
| CI | Buy | CIGNA CORPORATION | $11,708,000 | +31.4% | 57,650 | +21.0% | 1.22% | +31.2% |
| HZNP | Buy | HORIZON PHARMA PLC | $11,593,000 | +87.8% | 794,062 | +63.2% | 1.21% | +87.5% |
| MGNX | Buy | MACROGENICS INC | $10,724,000 | +33.9% | 564,401 | +30.3% | 1.12% | +33.8% |
| BGNE | New | BEIGENE LTDsponsored adr | $10,129,000 | – | 103,650 | +100.0% | 1.06% | – |
| MYL | Buy | MYLAN N V | $9,998,000 | +75.9% | 236,300 | +30.4% | 1.04% | +75.8% |
| SUPN | New | SUPERNUS PHARMACEUTICALS INC | $9,580,000 | – | 240,400 | +100.0% | 1.00% | – |
| LH | Buy | LABORATORY CORP AMER HLDGS | $9,063,000 | +9.8% | 56,820 | +3.9% | 0.95% | +9.7% |
| SHPG | Buy | SHIRE PLCsponsored adr | $8,754,000 | +34.7% | 56,435 | +33.0% | 0.92% | +34.6% |
| IART | Buy | INTEGRA LIFESCIENCES HLDGS C | $8,720,000 | -2.3% | 182,200 | +3.0% | 0.91% | -2.5% |
| HUM | Buy | HUMANA INC | $8,273,000 | +8.3% | 33,350 | +6.4% | 0.86% | +8.1% |
| TSRO | Buy | TESARO INC | $5,975,000 | +320.8% | 72,100 | +555.5% | 0.62% | +318.8% |
| HCM | Buy | HUTCHISON CHINA MEDTECH LTDsponsored adr | $5,258,000 | +200.3% | 133,850 | +107.3% | 0.55% | +200.0% |
| TFX | Buy | TELEFLEX INC | $3,483,000 | +41.1% | 14,000 | +37.3% | 0.36% | +41.1% |
| GNMK | Buy | GENMARK DIAGNOSTICS INC | $3,226,000 | -36.0% | 773,677 | +47.7% | 0.34% | -36.1% |
| HSIC | Buy | SCHEIN HENRY INC | $3,005,000 | -3.6% | 43,000 | +13.2% | 0.31% | -3.7% |
| LABU | New | DIREXION SHS ETF TRsp biotch bl new | $2,989,000 | – | 38,400 | +100.0% | 0.31% | – |
| SGEN | Buy | SEATTLE GENETICS INC | $2,862,000 | +16.9% | 53,500 | +18.9% | 0.30% | +16.8% |
| PTLA | Buy | PORTOLA PHARMACEUTICALS INC | $2,110,000 | +24.0% | 43,350 | +37.6% | 0.22% | +23.6% |
| SAGE | New | SAGE THERAPEUTICS INC | $2,084,000 | – | 12,650 | +100.0% | 0.22% | – |
| QTRX | New | QUANTERIX CORP | $1,799,000 | – | 83,800 | +100.0% | 0.19% | – |
| TRHC | Buy | TABULA RASA HEALTHCARE INC | $1,627,000 | +9.8% | 58,000 | +4.7% | 0.17% | +9.7% |
| IBB | Buy | ISHARES TRnasdaq biotech | $1,441,000 | -52.0% | 13,500 | +50.0% | 0.15% | -51.9% |
| ITCI | Buy | INTRA CELLULAR THERAPIES INC | $1,339,000 | +112.2% | 92,500 | +131.2% | 0.14% | +112.1% |
| CHRS | New | COHERUS BIOSCIENCES INC | $1,320,000 | – | 150,000 | +100.0% | 0.14% | – |
| ICPT | Buy | INTERCEPT PHARMACEUTICALS IN | $1,133,000 | +129.8% | 19,400 | +128.2% | 0.12% | +126.9% |
| OMCL | New | OMNICELL INC | $970,000 | – | 20,000 | +100.0% | 0.10% | – |
| CLLS | New | CELLECTIS S Asponsored ads | $710,000 | – | 24,350 | +100.0% | 0.07% | – |
| MLNT | New | MELINTA THERAPEUTICS INC | $507,000 | – | 32,100 | +100.0% | 0.05% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bellevue Asset Management AG #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.